Mizuho Securities analyst Difei Yang maintained a Buy rating on Viveve Medical Inc (VIVE) today and set a price target of $4. The company’s shares closed yesterday at $1.42, close to its 52-week low of $1.26.
Yang observed:
“We attended Viveve’s investor event on stress urinary incontinence (SUI) yesterday in NY. The event was well attended and informative (see our key takeaways below). Positive 12-month data from the SUI feasibility study was highlighted showing that 72% of patients experienced an overall mean improvement of 56% in the 1-hr pad weight test at 12-months. With a recently completed $18.8 mil common stock offering, we believe Viveve has sufficient cash to reach the important LIBERATE INTL 6-month readout in early 3Q19. We expect results from this trial will be an important catalyst for the shares.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 16.6% and a 45.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viveve Medical Inc with a $4.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.25 and a one-year low of $1.26. Currently, Viveve Medical Inc has an average volume of 275.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Viveve Medical, Inc. engages in the provision of health products. Its activities include development and distribution of women’s health solutions. Its products include non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. The company was founded on March 3, 1987 and is headquartered Englewood, CO.
